Pulmonary hypertension: Hemodynamic evaluation. Updated Recommendations of the Cologne Consensus Conference 2011

International Journal of Cardiology

Volumn 154, Issue SUPPL. 1, 2011, Pages

  Opitz, Christian F ^a,b   Blindt, Rüdiger ^c   Blumberg, Friedrich ^d   Borst, Mathias M ^e   Bruch, Leonhard ^f   Leuchte, Hanno H ^g   Lichtblau, Mona ^h   Nagel, Christian ^h   Peters, Klaus ⁱ   Rosenkranz, Stephan ^j   Schranz, Dietmar ^k   Skowasch, Dirk ^l   Tiede, Henning ^m   Weil, Joachim ⁿ   Ewert, Ralf ^b  

^a German Red Cross Hospital   (Germany)

^b UNIVERSITY OF GREIFSWALD   (Germany)

^c Kardio Nord   (Germany)

^d PROSPER HOSPITAL   (Germany)

^e CARITAS KRANKENHAUS   (Germany)

^f Clinic for Internal Medicine   (Germany)

^g Hospital Neuwittelsbach   (Germany)

^h UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

ⁱ UNIVERSITY HEART CENTER FREIBURG BAD KROZINGEN   (Germany)

^j UNIVERSITY OF COLOGNE   (Germany)

^k JUSTUS LIEBIG UNIVERSITY   (Germany)

^l UNIVERSITY HOSPITAL BONN   (Germany)

^m UNIVERSITY HOSPITAL GIESSEN   (Germany)

ⁿ UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

more..

Author keywords

Hemodynamic evaluation; Pulmonary hypertension; Right heart catheter; Vasoreactivity testing

Indexed keywords

ADENOSINE; CALCIUM CHANNEL BLOCKING AGENT; ENDOTHELIN RECEPTOR ANTAGONIST; ILOPROST; INOTROPIC AGENT; NITRIC OXIDE; PHOSPHODIESTERASE V INHIBITOR; PROSTACYCLIN; PROSTANOID; SILDENAFIL; VASODILATOR AGENT;

ANGINA PECTORIS; ANGIOCARDIOGRAPHY; BLOOD VESSEL REACTIVITY; CARDIOLOGY; CARDIOPULMONARY HEMODYNAMICS; CHILD HEALTH CARE; CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION; CLINICAL DECISION MAKING; CLINICAL EVALUATION; CONFERENCE PAPER; CONNECTIVE TISSUE DISEASE; CONSENSUS DEVELOPMENT; CORONARY ARTERY DISEASE; DIAGNOSTIC PROCEDURE; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; DRUG SCREENING; ECHOCARDIOGRAPHY; EUROPE; FOLLOW UP; GENERAL ANESTHESIA; GERMANY; HEALTH CARE ORGANIZATION; HEALTH CARE PLANNING; HEART CATHETERIZATION; HEART DISEASE; HEART OUTPUT; HEART RIGHT ATRIUM PRESSURE; HEART RIGHT VENTRICLE PRESSURE; HEART VENTRICLE ENDDIASTOLIC PRESSURE; HUMAN; HYPOXEMIA; INVASIVE PROCEDURE; LUNG ARTERY PRESSURE; LUNG DISEASE; LUNG TRANSPLANTATION; LUNG VASCULAR RESISTANCE; NORMAL VALUE; OXYGEN SATURATION; OXYGEN THERAPY; PATIENT CODING; PATIENT REFERRAL; PEDIATRIC CARDIOLOGY; PORTAL HYPERTENSION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; PULMONARY ARTERY; PULMONARY ARTERY OCCLUSION PRESSURE; PULMONARY HYPERTENSION; PULMONARY VENO-OCCLUSIVE DISEASE; PULMONOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; SUPERIOR CAVA VEIN; TREATMENT INDICATION; TREATMENT RESPONSE; VASODILATATION;

CHILD; HEMODYNAMICS; HUMANS; HYPERTENSION, PULMONARY; PRACTICE GUIDELINES AS TOPIC; PULMONARY MEDICINE;

EID: 84855396906     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/S0167-5273(11)70489-2     Document Type: Conference Paper

References (38)

1. Galiè N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009;30:2493-537.
2. Galiè N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Respir J 2009;34:1219-63.
3. Hoeper MM, Ghofrani HA, Gorenflo M, et al. Diagnosis and Treatment of Pulmonary Hypertension: European Guidelines 2009. Pneumologie 2010;64:401-14.
4. Humbert M, Sitbon O, Chaouat A, et al. Pulmonary Arterial Hypertension in France: Results from a National Registry. Am J Respir Crit Care Med 2006;173:1023-30.
5. Peacock AJ, Murphy NF, McMurray JJ, Caballero L, Stewart S. An epidemiological study of pulmonary arterial hypertension. Eur Respir J 2007;30:104-9. (Pubitemid 47074013)
6. Dalonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991;115:343-9.
7. Kovacs G, Berghold A, Scheidl S, Olschewski H. Pulmonary arterial pressure during rest and exercise in healthy subjects: a systematic review. Eur Respir J 2009;34:888-94.
8. Naeije R, Melot C, Niset G, Delcroix M, Wagner PD. Mechanisms of improved arterial oxygenation after peripheral chemoreceptor stimulation during hypoxic exercise. J Appl Physiol 1993;74:1666-71. (Pubitemid 23133457)
9. Bonderman D, Wexberg P, Martischnig AM, et al. A non-invasive algorithm to exclude precapillary pulmonary hypertension. Eur Respir J 2010; Sept 3 [E-Pub ahead of print].
10. Hoeper MM, Lee SH, Voswinckel R, et al. Complications of right heart catheterization procedures in patients with pulmonary hypertension in experienced centers. J Am Coll Cardiol 2006;48:2546-52. (Pubitemid 44881214)
11. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992;327:76-81.
12. Sitbon O, Humbert M, Jais X, et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 2005;111:3105-11. (Pubitemid 40847788)
13. Galie N, Ussia G, Passarelli P, et al. Role of pharmacologic tests in the treatment of primary pulmonary hypertension. Am J Cardiol 1995;75:55A-62A.
14. McLaughlin VV, Genthner DE, Panella MM, Rich S. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N Engl J Med 1998;338:273-7. (Pubitemid 28065252)
15. Jing ZC, Jiang X, Han ZY, et al. Iloprost for pulmonary vasodilator testing in idiopathic pulmonary arterial hypertension. Eur Respir J 2009;33:1354-60.
16. Opitz CF, Rubin LJ. Acute vasodilator testing in idiopathic pulmonary arterial hypertension: must we take NO for the answer? Eur Respir J 2009;33:1247-9.
17. Oliveira EC, Ribero AL, Amaral CF. Adenosine for vasoreactivity testing in pulmonary hypertension: A head-to-head comparison with inhaled nitric oxide. Respir Med 2010;104:606-11.
18. Tonelli AR, Alnuaimat H, Mubarak K. Pulmonary vasodilator testing and use of calcium channel blockers in pulmonary arterial hypertension. Respir Med 2010;104:481-96.
19. Thenappan T, Shah SJ, Rich S, et al. Survival in pulmonary arterial hypertension: a reappraisal of the NIH risk stratification equation. Eur Respir J 2010; 35:1079-87.
20. Higenbottam T, Butt AY, McMahon A, Westerbeck R, Sharples L. Long-term intravenous prostaglandin (epoprostenol or iloprost) for treatment of severe pulmonary hypertension. Heart 1998;80:151-5. (Pubitemid 28389476)
21. Wensel R, Opitz CF, Anker SD, et al. Assessment of survival in patients with primary pulmonary hypertension: importance of cardiopulmonary exercise testing. Circulation 2002;106:319-24. (Pubitemid 34778955)
22. Thabut G, Dauriat G, Stern JB, et al. Pulmonary hemodynamics in advanced COPD candidates for lung volume reduction surgery or lung transplantation. Chest 2005;127:1531-6. (Pubitemid 46218776)
23. Sitbon O, Humbert M, Nunes H, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 2002;40:780-8. (Pubitemid 34925627)
24. Sitbon O, McLaughlin VV, Badesch DB, et al. Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol. Thorax 2005;60:1025-30. (Pubitemid 41705471)
25. McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 2002;106:1477-82.
26. McLaughlin VV, Sitbon O, Badesch DB, et al. Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J 2005;25:244-9. (Pubitemid 40246523)
27. Castelain V, Chemla D, Humbert M, et al. Pulmonary artery pressure-flow relations after prostacyclin in primary pulmonary hypertension. Am J Respir Crit Care Med 2002;165:338-40. (Pubitemid 34118505)
28. Blumberg FC, Riegger GA, Pfeifer M. Hemodynamic effects of aerosolized iloprost in pulmonary hypertension at rest and during exercise. Chest 2002;121:1566-71. (Pubitemid 34499672)
29. Zimmermann R, Kreuder J, Michel-Behnke I, Voelkel NF, Schranz D. Pulmonary flow reserve in children with idiopathic pulmonary arterial hypertension: implications for diagnosis and therapy. Eur J Med Res 2006;11:208-13.
30. Gorenflo M, Bettendorf M, Brockmeier K, Ulmer HE. Pulmonary vasoreactivity and vasoactive mediators in children with pulmonary hypertension. Z Kardiol 2000;89:1000-8.
31. Raffy O, Azarian R, Brenot F, et al. Clinical significance of the pulmonary vasodilator response during short-term infusion of prostacyclin in primary pulmonary hypertension. Circulation 1996;93:484-8.
32. Halpern SD, Taichman DB. Misclassification of pulmonary hypertension due to reliance on pulmonary capillary wedge pressure rather than left-ventricular end-diastolic pressure. Chest 2009;136:37-43.
33. Bundesärztekammer. Richtlinie zur Organtransplantation gemäß §16 Transplantationsgesetz. Dtsch Arztebl 2000;97:A-396/B-333/C-310.
34. Natale ME, Pina IL. Evaluation of pulmonary hypertension in heart transplant candidates. Curr Opin Cardiol 2003;18:136-40.
35. Delgado JF, Gomez-Sanchez MA, Saenz de la Calzada C, et al. Impact of mild pulmonary hypertension on mortality and pulmonary artery pressure profile after heart transplantation. J Heart Lung Transplant 2001;20:942-8. (Pubitemid 32824139)
36. Sablotzki A, Czeslick E, Gruenig E, et al. First experiences with the stable prostacyclin analog iloprost in the evaluation of heart transplant candidates with increased pulmonary vascular resistance. J Thorac Cardiovasc Surg 2003;125:960-2. (Pubitemid 36457524)
37. Lepore JJ, Maroo A, Pereira NL, et al. Effect of sildenafil on the acute pulmonary vasodilator response to inhaled nitric oxide in adults with primary pulmonary hypertension. Am J Cardiol 2002;90:677-80. (Pubitemid 35264557)
38. von Scheidt W, Costard-Jaeckle A, Stempfle HU, et al. Prostaglandin E1 testing in heart failure-associated pulmonary hypertension enables transplantation: the PROPHET study. J Heart Lung Transplant 2006;25:1070-6. (Pubitemid 44322050)